Pandey et al., pp. 2520–2533 Hypermethylation of the gluthathione-S-transferase pi (GSTP1) promoter is detected in over 90% of invasive prostate cancer biopsies. Reversing the process of DNA methylation using DNA methyltransferase inhibitors exerts anti-cancer effects. However, this process can also result in the demethylation–and by extension the activation–of prometastatic genes, causing genomic instability, increased cancer aggressiveness and cellular toxicity. Green tea polyphenols (GTPs) have various anti-cancer effects. One study showed that GTPs are able to inhibit DNA methyltransferase and reactivate methylation-silenced genes in cancer cells. In this report, Pandey et al. investigate whether GTPs offer an alternative way of reactivating GSTP1 without causing the pathological or toxic effects that standard methyltransferase inhibitors such as 5-Aza-dC do. Using prostate cancer cell lines, GTP was shown to inhibit DNA methyltransferase activity and reactivate GSTP1 expression in a dose- and time-dependent manner. The authors showed that treatment of prostate cancer cells with GTP for 7 days resulted in the demethylation of the proximal GSTP1 promoter. Exposure to GTP also caused a drop in methyl-binding protein expression–proteins which are known to contribute to hypermethylated gene silencing. Notably, GTP promoted chromatin stability by inhibiting histone deacetylase activity. The most striking finding in this study was that GTP's demethylation effect was specific to GSTP1. Unlike 5-Aza-dC, it did not appear to cause the genome-wide demethylatation that is associated with inadvertent activation of prometastatic genes and cell toxicity. These experiments show that GTPs can exert two positive epigenetic effects: promoting specific DNA demethylation and chromatin stability without excessive toxicity. GTPs offer the promise of superior in vivo anti-cancer effects relative to the methyltransferase inhibitor 5-Aza-dC and warrant further study. Zhang et al., pp. 2534–2541 The early stages of metastasis are difficult to characterize using histological methods. In this report Zhang et al., employ a small animal imaging system (OV100) and fluorescence molecular tomography imager (VisEn) in vivo to study early metastasis in the GFP-PC-3 prostate cancer mouse model, which mirrors metastasis in patients. Using the OV100 imaging system, extensive GFP-PC-3 cells were visualized in the liver vasculature of live tumor-bearing mice through an abdominal skin flap. No tumor foci could be found in extravascular tissue. Far less extensive intravascular metastasis was found in the lungs of tumor-bearing mice. Matrix metalloproteinases (MMP) activity was tracked in both organs using a fluorescence probe. Z-stack images showed that GFP-PC-3 cancer cells produce active MMP in vivo. Additional VisEn imaging offered picomolar sensitivity and spatial resolution measurements: tumor-bearing mice showed 3 times higher MMP activity than control animals and the signal was stronger in the liver than in the lung. Dissected liver and lungs from tumor-bearing mice confirmed the in vivo observations. Metastasized liver cells were found in small and large vessels as clusters of up to 100 cells. No extravasation was observed 3 weeks after primary tumor inoculation. In lung tissue, smaller clusters (10 cells or less) were seen mainly in the pulmonary micro-vessels although extravascular metastasis was observed in the hilar region. This study demonstrates that PC-3 cells gather in the blood vessels of secondary organs to proliferate and develop into metastatic cells. This combined in vivo imaging technique offers a new opportunity to study the intravascular microenvironment and process of metastasis in vivo. Bastos et al., pp. 2700–2715 National public health strategies for cancer vary greatly. On page 2700, Bastos et al. present a comprehensive view of 2008 cancer control structures in 27 European Union member countries in addition to Norway, Iceland and Switzerland. The report draws on a number of sources and offers useful definitions of the provisions described. Just over half of the countries had cancer plans in place. Cancer registries are much more common; only Greece and Luxembourg didn't have a population-based registry and the majority of registries offer national coverage. Seventeen of the countries had a breast cancer screening program but participant rates varied from 25 to 85%. Participation rates were more extreme for cervical cancer screening programs, ranging from 10 to 80%. Newer programs coming on stream include HPV vaccination, colorectal cancer screening and smoking restrictions but implementation is still patchy across Europe. The authors stress that good cancer control structures do not automatically guarantee quality of care. This report clearly demonstrates the heterogeneity in cancer structures across Europe and offers the opportunity for inter-country co-operation and sharing of best practice.
Read full abstract